Tag: Generic latisse

According to the FDA, generic Latisse contains the same active ingredient as the brand-name version and is considered therapeutically equivalent. This means that for individuals with hypotrichosis of the eyelashes, **generic Latisse** is just as effective at stimulating longer, thicker, and darker lash growth as the more expensive brand.

While Latisse was first approved by the FDA in December 2008 [1.6.1], the answer to **when did Latisse go generic** is more complex. The first generic approvals appeared years before the final patents expired in 2024, offering a more affordable option for treating eyelash hypotrichosis [1.2.1, 1.2.3].

Generic Latisse, known by its active ingredient bimatoprost, is the only FDA-approved prescription treatment for growing eyelashes that have become sparse or inadequate. This clinically proven ophthalmic solution enhances the length, thickness, and darkness of a person's natural lashes.